Clinical trials: Drug Eluting Stents
Coronary Disease
Mechanism of Percutaneous Revascularization for Coronary Bifurcation Disease
The main objectives of this study are define frequency of plaque shift phenomenon and impact on flow dynamics in the side branch as assessed by intravascular ultrasound, and evaluate acute and late side branch ostial vessel…
- Trial name
- NCT00429052
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Coronary Artery Disease, Coronary Restenosis
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR
AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs.
- Trial name
- AbsorbISR (NCT02474485)
- Testing
- BVS Absorb implantation., DEB Sequent Please inflation., Control coronary angiography.
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- SIS Medical AG
Ischemic Heart Disease
Long-term Outcomes and Prognostic Factors in Patient Undergoing CABG or PCI
1. To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary artery disease undergoing coronary artery bypass graft surgery. 2.
- Trial name
- NCT03870815
- Testing
- CABG, PCI
- Where
- South Korea
- Volunteers
- 10,000 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease, Restenosis
Culotte Technique Versus TAP Stunting for the Treatment of de Novo Coronary Bifurcation Lesion With Drug-eluting Stents
BBK- 2 - study: STUDY-SUMMARY Background: The need for stenting of the main and side branch (double stenting) in the treatment of coronary bifurcation lesion primarily depends on the complexity of the bifurcation lesion.
- Trial name
- BBK2 (NCT01267838)
- Testing
- PCI
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Coronary Artery Disease
Procedural Advantages of a Novel Drug-Eluting Coronary Stent
This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.
- Trial name
- NCT02881216
- Testing
- Synergy Stent, Currently common drug-eluting stent (DES)
- Volunteers
- 814 people
- Sponsor
- University Hospital Heidelberg
Coronary Artery Disease, Coronary Artery Stenosis
ABSORB III Randomized Controlled Trial (RCT)
The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS).
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB-III (NCT01751906)
- Testing
- Absorb BVS, XIENCE
- Where
- 192 sites in United States, Australia
- Volunteers
- 2,008 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Retrospective Study of the Impact of Drug Eluting Stents
The purpose of this study is to determine whether the use of drug eluting stents is associated with higher rates of death, myocardial infarction, and major bleeding.
- Trial name
- NCT00487604
- Where
- United States
- Volunteers
- 9,800 people
- Sponsor
- Providence Health & Services
Stable Angina, Unstable Angina
Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population
The aim of this study is to evaluate safety and efficacy performances of CRE8 Drug Eluting Stent, in patients comparable to the everyday's clinical practice population, with a specific focus on diabetics, that will be part of a…
- Conditions
- Stable Angina, Unstable Angina, Acute Myocardial Infarction
- Trial name
- PARTICIPATE (NCT01556126)
- Testing
- Amphilimus Eluting Stent (CRE8)
- Where
- 23 sites in Austria, Belgium and 4 more
- Volunteers
- 1,191 people
- Sponsor
- CID - Carbostent & Implantable Devices
Coronary Artery Disease
IRIS-Synergy Cohort in the IRIS-DES Registry
The purpose of this study is to evaluate the relative effectiveness and safety of Synergy stent compared to other drug eluting stents.
- Trial name
- IRIS Synergy (NCT02720419)
- Where
- 28 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Jung-min Ahn
Coronary Artery Disease
Serial OCT Evaluation of Tissue Coverage in Patients Submitted to Inspiron Drug Eluting Stent Implantation
Prospective, multicentric, single-arm study to evaluate fast and effective tissue repair in patients undergone percutaneous coronary intervention with drug eluting stent Inspiron.
- Trial name
- REPAIR (NCT03269461)
- Testing
- Angiography and Optical Coherence Tomography evaluations
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Scitech Produtos Medicos SA
Coronary Heart Disease, Diabetes Mellitus
Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT
Diabetic patients are prone to a diffuse and rapidly progressive form of atherosclerosis. Both clinical and angiographic outcomes following percutaneous coronary intervention (PCI) are poor in patients with DM compared with those…
- Trial name
- DM-COVER (NCT01021930)
- Testing
- Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Harbin Medical University
Myocardial Infarction, Percutaneous Coronary Intervention
Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome
The purpose of the prospective, randomized and a multicenter trial is to compare clinical outcome in patients presenting with ACS, treated with PCI using Optimax-BAS versus Synergy-EES.
- Conditions
- Myocardial Infarction, Percutaneous Coronary Intervention, Atherosclerosis
- Trial name
- TIDES-ACS (NCT02049229)
- Testing
- percutaneous coronary intervention
- Where
- 6 sites in Finland
- Volunteers
- 1,800 people
- Sponsor
- The Hospital District of Satakunta
Coronary Thrombosis, Tomography, Optical Coherence
Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis
Bioresorbable vascular scaffold (BVS, ABSORB BVS1.1, Abbott Vascular) has been approved (CE mark) and is used in daily clinical practice.
- Conditions
- Coronary Thrombosis, Tomography, Optical Coherence, Drug-Eluting Stents
- Trial name
- INVEST (NCT03180931)
- Testing
- Bioresorbable vascular scaffold
- Where
- 19 sites in Austria, Belgium and 8 more
- Volunteers
- 36 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Symptomatic Peripheral Artery Disease With Femoropopliteal Lesions, Moderate or Severe Claudication (Rutherford Category 2 or 3)
Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease (K-ELUVIA Registry)
Prospective, multi-center single-arm observational study A total of 100 subjects with femoropopliteal artery disease who meet all inclusion and exclusion criteria will be included.
- Conditions
- Symptomatic Peripheral Artery Disease With Femoropopliteal Lesions, Moderate or Severe Claudication (Rutherford Category 2 or 3), Critical Limb Ischemia (Rutherford Category 4 or 5)
- Trial name
- NCT03505931
- Testing
- Implantation of Eluvia stent
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Cardiovascular Diseases
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population
The primary objective of the RESOLUTE international registry is to document the safety and overall clinical performance of the Resolute Zotarolimus-Eluting Coronary Stent System in a 'real-world' patient population requiring…
- Trial name
- R-Int (NCT00752128)
- Testing
- Endeavor Resolute Zotarolimus-Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 2,349 people
- Sponsor
- Medtronic Vascular
Vertebral Artery Stenosis
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis.
- Trial name
- M Short DAPT (NCT06683300)
- Testing
- DAPT for 3 months after vertebral artery stenting
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Beijing Tiantan Hospital
Coronary Artery Disease
The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.
The main objective of this study is to assess the safety and effectiveness of the sirolimus coated Bx VELOCITY stent in reducing angiographic in-stent late loss in de novo native coronary lesions as compared to the bare metal Bx…
- Trial name
- RAVEL (NCT00233805)
- Testing
- Sirolimus coated Bx Velocity™, Bare metal Bx Velocity™
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Cordis US Corp.
Ischemic Heart Disease
Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)
The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thrombosis resulting in less deaths and…
- Trial name
- PROTECT (NCT00476957)
- Testing
- Stent
- Where
- Netherlands
- Volunteers
- 8,709 people
- Sponsor
- Medtronic Vascular
Diabetes Mellitus
BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY
The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis…
- Trial name
- BLADE (NCT02645799)
- Testing
- LABR-312
- Where
- Israel
- Volunteers
- 270 people
- Sponsor
- BIOrest Ltd.
Coronary Artery Disease
Drug Eluting Balloon Versus Drug Eluting Stent in PCI
Drug eluting balloons (DEB) have been developed to overcome the limitations of drug eluting stent (DES), but clinical results of different studies about DEB are not consistent.
- Trial name
- NCT01760200
- Where
- Italy
- Volunteers
- 1,462 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita